Is it better to buy straddle-To The Moon - Tiger Brokers Online Investing Community - To The Moon

4
1
Favorite

dgsean0813
2025-09-16

Is it better to buy straddle

Option Strategy | Novo Nordisk’s Obesity Breakthroughs Boost Case for Long-Term Call Bets

$Novo Nordisk(NVO)$ continues to make headlines as the World Health Organization backs weight-loss drugs for obesity and the EU clears its oral semaglutide for cardiovascular risk reduction.These...

Option Strategy | Novo Nordisk’s Obesity Breakthroughs Boost Case for Long-Term Call Bets

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

4

Report

Comment（1）

Top
Latest

Dan1192
·2025-09-17
TOP
我转而购买了leaps，认为NVO的PE比Ely便宜得多。就品牌而言，我们看到这两个品牌同样知名，因此品牌溢价并不能证明PE的差距是合理的。NVO最终应该会赶上向上
Reply
Like
Report

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":479273100493328,"tweetId":"479273100493328","gmtCreate":1758036853025,"gmtModify":1758038593286,"author":{"id":4173663574658622,"idStr":"4173663574658622","authorId":4173663574658622,"authorIdStr":"4173663574658622","name":"dgsean0813","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Is it better to buy straddle&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Is it better to buy straddle&nbsp;</p></body></html>","text":"Is it better to buy straddle","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":1,"favoriteSize":0,"link":"https://ttm.financial/post/479273100493328","repostId":1133329147,"repostType":2,"repost":{"id":"1133329147","kind":"news","weMediaInfo":{"introduction":"Magic option strategies for extra income.","home_visible":1,"media_name":"Option Witch","id":"1016323842","head_image":"https://community-static.tradeup.com/news/7471350466f20d36ee3112d77c72cd89"},"pubTimestamp":1758035794,"share":"https://ttm.financial/m/news/1133329147?lang=en_US&edition=fundamental","pubTime":"2025-09-16 23:16","market":"us","language":"en","title":"Option Strategy | Novo Nordisk’s Obesity Breakthroughs Boost Case for Long-Term Call Bets","url":"https://stock-news.laohu8.com/highlight/detail?id=1133329147","media":"Option Witch","summary":"$Novo Nordisk(NVO)$ continues to make headlines as the World Health Organization backs weight-loss drugs for obesity and the EU clears its oral semaglutide for cardiovascular risk reduction.These...","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> continues to make headlines as the World Health Organization backs weight-loss drugs for obesity and the EU clears its oral semaglutide for cardiovascular risk reduction.</p><p>These milestones highlight the company’s growing dominance in the GLP-1 market, positioning it for sustained growth in both obesity and diabetes care.</p><p>Long-term call options offer an attractive way to capture NVO’s upside. Whether deep-in-the-money or out-of-the-money, these strategies let investors participate in Novo Nordisk’s growth with defined risk and significantly lower capital outlay than buying shares outright.</p><h3 id=\"id_1448239176\">WHO Backs Weight-Loss Drugs for Obesity</h3><p>The World Health Organization will recommend using weight-loss drugs to treat obesity in adults, according to draft guidance from the agency that urged countries to take the condition seriously as a chronic disease.</p><p>The WHO’s expert committee concluded that the popular <strong>GLP-1 drugs, first developed by <a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk</a> and <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a></strong>, are part of the solution for the long-term treatment of obesity for patients with a body mass index (BMI) of 30 or above, alongside counselling on lifestyle and behaviour changes.</p><p>It <strong>recommended using the drugs to treat obesity for the first time</strong>, calling it a critical step toward developing a global standard of care. It is developing separate guidelines for treating children and adolescents.</p><h3 id=\"id_1462440261\">Novo Nordisk to Test Weight-Loss Drugs</h3><p>Novo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat <strong>a wide range of health conditions linked to obesity</strong>, as it has already begun doing with its blockbuster drug Wegovy.</p><p>The Danish drugmaker <strong>aims to build evidence across both severe and more common obesity-related conditions that affect patients&#39; daily lives</strong>, such as knee osteoarthritis and sleep apnea, Martin Holst Lange, head of research and development at Novo Nordisk said</p><h3 id=\"id_2026099614\" style=\"text-align: left;\">EU Clears Novo&#39;s Oral Semaglutide for Heart Risk Reduction</h3><p>The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved Danish pharma major <strong>Novo Nordisk’s update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.</strong></p><p>“Heart problems are the leading cause of disability and death for people living with type 2 diabetes. Therefore, treatments that also address heart problems are key to improving not only health outcomes, but also quality of life – and this approval will help do just that,” said Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk. “This milestone makes semaglutide <strong>the only oral GLP-1 RA with proven blood glucose and body weight reduction, as well as cardiovascular benefits</strong>.”</p><h3 id=\"id_4126014390\">NVO’s OI Shows Bullish Bets</h3><p>Open interest for NVO expiring in a year (before Sep 18, 2026 expiration) showed moderately bullish sentiment as <strong>Call</strong> open interest totaled at <strong>534,364</strong>, while<strong> Puts </strong>stood at <strong>468,000</strong>. Put-Call open interest ratio reached <strong>0.88</strong>.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c0ef78bcfcb2867db86eba0672df31f5\" title=\"Source: Option Charts\" tg-width=\"981\" tg-height=\"711\"/><span>Source: Option Charts</span></p><h3 id=\"id_2101600224\">Option Strategy: Buy Long-Term Call</h3><p>The expected move for <strong>NVO</strong> options expiring on <strong>Sep 18, 2026 (367 days)</strong> is <strong>±$16.39 (29.25%)</strong>, with a price range of <strong>$39.64 - $72.42</strong>.</p><p>The expected move means that IV implies the stock price has a probability of rising toward <strong>$72</strong> in a year, giving chances to buy long-term call options for bullish investors.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/985b08fe4c52a0dc8262938afb458718\" title=\"Source: Option Charts\" tg-width=\"972\" tg-height=\"788\"/><span>Source: Option Charts</span></p><h4 id=\"id_2362700344\">Strategy 1: Buy ITM Call</h4><p>Conservative investors may consider deep ITM call options. With <strong>high intrinsic value</strong> and low time value, these options are <strong>less vulnerable to time decay</strong>, making them effective for long-term investing or hedging.</p><p>ITM options carry <strong>higher premiums </strong>than ATM or OTM ones, but still cost far less than buying the underlying asset outright. This allows investors to control a larger asset value with a smaller capital outlay.</p><p><strong>Example:</strong> Buy the <strong>$40 strike call option </strong>( Sep 18, 2026 expiration)</p><p><a class=\"teditor-mention\" data-mention-id=\"NVO 20260918 40.0 CALL\" data-mention-name=\"NVO\" href=\"https://ttm.financial/OPT/NVO%2020260918%2040.0%20CALL\">$NVO 20260918 40.0 CALL$</a></p><ul style=\"\"><li><p><strong>Max Profit</strong>: +∞</p></li><li><p><strong>Net Debit</strong>: $1,995 (est.)</p></li><li><p><strong>Breakeven</strong>: $59.95</p></li></ul><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/a1720a76655d04684a63792a9db4e1e9\" tg-width=\"1170\" tg-height=\"1355\"/></p><h4 id=\"id_659007363\">Strategy 2: Buy OTM Call</h4><p>Out-of-the-money options come with lower premiums, making them attractive to investors with limited capital but higher risk tolerance. They provide a low-cost way to gain exposure to potential upside in the underlying asset.</p><p><strong>Example: </strong>Buy the <strong>$70 strike call option </strong>( Sep 18, 2026 expiration)</p><p><a class=\"teditor-mention\" data-mention-id=\"NVO 20260918 70.0 CALL\" data-mention-name=\"NVO\" href=\"https://ttm.financial/OPT/NVO%2020260918%2070.0%20CALL\">$NVO 20260918 70.0 CALL$</a></p><ul style=\"\"><li><p><strong>Max Profit</strong>: +∞</p></li><li><p><strong>Net Debit</strong>: $590 (est.)</p></li><li><p><strong>Breakeven</strong>: $75.90</p></li></ul><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/6604ed959eba1b39c1e375099592a128\" tg-width=\"1170\" tg-height=\"1356\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Option Strategy | Novo Nordisk’s Obesity Breakthroughs Boost Case for Long-Term Call Bets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOption Strategy | Novo Nordisk’s Obesity Breakthroughs Boost Case for Long-Term Call Bets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016323842\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/7471350466f20d36ee3112d77c72cd89);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Option Witch </p>\n<p class=\"h-time\">2025-09-16 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> continues to make headlines as the World Health Organization backs weight-loss drugs for obesity and the EU clears its oral semaglutide for cardiovascular risk reduction.</p><p>These milestones highlight the company’s growing dominance in the GLP-1 market, positioning it for sustained growth in both obesity and diabetes care.</p><p>Long-term call options offer an attractive way to capture NVO’s upside. Whether deep-in-the-money or out-of-the-money, these strategies let investors participate in Novo Nordisk’s growth with defined risk and significantly lower capital outlay than buying shares outright.</p><h3 id=\"id_1448239176\">WHO Backs Weight-Loss Drugs for Obesity</h3><p>The World Health Organization will recommend using weight-loss drugs to treat obesity in adults, according to draft guidance from the agency that urged countries to take the condition seriously as a chronic disease.</p><p>The WHO’s expert committee concluded that the popular <strong>GLP-1 drugs, first developed by <a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk</a> and <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a></strong>, are part of the solution for the long-term treatment of obesity for patients with a body mass index (BMI) of 30 or above, alongside counselling on lifestyle and behaviour changes.</p><p>It <strong>recommended using the drugs to treat obesity for the first time</strong>, calling it a critical step toward developing a global standard of care. It is developing separate guidelines for treating children and adolescents.</p><h3 id=\"id_1462440261\">Novo Nordisk to Test Weight-Loss Drugs</h3><p>Novo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat <strong>a wide range of health conditions linked to obesity</strong>, as it has already begun doing with its blockbuster drug Wegovy.</p><p>The Danish drugmaker <strong>aims to build evidence across both severe and more common obesity-related conditions that affect patients&#39; daily lives</strong>, such as knee osteoarthritis and sleep apnea, Martin Holst Lange, head of research and development at Novo Nordisk said</p><h3 id=\"id_2026099614\" style=\"text-align: left;\">EU Clears Novo&#39;s Oral Semaglutide for Heart Risk Reduction</h3><p>The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved Danish pharma major <strong>Novo Nordisk’s update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.</strong></p><p>“Heart problems are the leading cause of disability and death for people living with type 2 diabetes. Therefore, treatments that also address heart problems are key to improving not only health outcomes, but also quality of life – and this approval will help do just that,” said Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk. “This milestone makes semaglutide <strong>the only oral GLP-1 RA with proven blood glucose and body weight reduction, as well as cardiovascular benefits</strong>.”</p><h3 id=\"id_4126014390\">NVO’s OI Shows Bullish Bets</h3><p>Open interest for NVO expiring in a year (before Sep 18, 2026 expiration) showed moderately bullish sentiment as <strong>Call</strong> open interest totaled at <strong>534,364</strong>, while<strong> Puts </strong>stood at <strong>468,000</strong>. Put-Call open interest ratio reached <strong>0.88</strong>.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c0ef78bcfcb2867db86eba0672df31f5\" title=\"Source: Option Charts\" tg-width=\"981\" tg-height=\"711\"/><span>Source: Option Charts</span></p><h3 id=\"id_2101600224\">Option Strategy: Buy Long-Term Call</h3><p>The expected move for <strong>NVO</strong> options expiring on <strong>Sep 18, 2026 (367 days)</strong> is <strong>±$16.39 (29.25%)</strong>, with a price range of <strong>$39.64 - $72.42</strong>.</p><p>The expected move means that IV implies the stock price has a probability of rising toward <strong>$72</strong> in a year, giving chances to buy long-term call options for bullish investors.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/985b08fe4c52a0dc8262938afb458718\" title=\"Source: Option Charts\" tg-width=\"972\" tg-height=\"788\"/><span>Source: Option Charts</span></p><h4 id=\"id_2362700344\">Strategy 1: Buy ITM Call</h4><p>Conservative investors may consider deep ITM call options. With <strong>high intrinsic value</strong> and low time value, these options are <strong>less vulnerable to time decay</strong>, making them effective for long-term investing or hedging.</p><p>ITM options carry <strong>higher premiums </strong>than ATM or OTM ones, but still cost far less than buying the underlying asset outright. This allows investors to control a larger asset value with a smaller capital outlay.</p><p><strong>Example:</strong> Buy the <strong>$40 strike call option </strong>( Sep 18, 2026 expiration)</p><p><a class=\"teditor-mention\" data-mention-id=\"NVO 20260918 40.0 CALL\" data-mention-name=\"NVO\" href=\"https://ttm.financial/OPT/NVO%2020260918%2040.0%20CALL\">$NVO 20260918 40.0 CALL$</a></p><ul style=\"\"><li><p><strong>Max Profit</strong>: +∞</p></li><li><p><strong>Net Debit</strong>: $1,995 (est.)</p></li><li><p><strong>Breakeven</strong>: $59.95</p></li></ul><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/a1720a76655d04684a63792a9db4e1e9\" tg-width=\"1170\" tg-height=\"1355\"/></p><h4 id=\"id_659007363\">Strategy 2: Buy OTM Call</h4><p>Out-of-the-money options come with lower premiums, making them attractive to investors with limited capital but higher risk tolerance. They provide a low-cost way to gain exposure to potential upside in the underlying asset.</p><p><strong>Example: </strong>Buy the <strong>$70 strike call option </strong>( Sep 18, 2026 expiration)</p><p><a class=\"teditor-mention\" data-mention-id=\"NVO 20260918 70.0 CALL\" data-mention-name=\"NVO\" href=\"https://ttm.financial/OPT/NVO%2020260918%2070.0%20CALL\">$NVO 20260918 70.0 CALL$</a></p><ul style=\"\"><li><p><strong>Max Profit</strong>: +∞</p></li><li><p><strong>Net Debit</strong>: $590 (est.)</p></li><li><p><strong>Breakeven</strong>: $75.90</p></li></ul><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/6604ed959eba1b39c1e375099592a128\" tg-width=\"1170\" tg-height=\"1356\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133329147","content_text":"Novo Nordisk continues to make headlines as the World Health Organization backs weight-loss drugs for obesity and the EU clears its oral semaglutide for cardiovascular risk reduction.These milestones highlight the company’s growing dominance in the GLP-1 market, positioning it for sustained growth in both obesity and diabetes care.Long-term call options offer an attractive way to capture NVO’s upside. Whether deep-in-the-money or out-of-the-money, these strategies let investors participate in Novo Nordisk’s growth with defined risk and significantly lower capital outlay than buying shares outright.WHO Backs Weight-Loss Drugs for ObesityThe World Health Organization will recommend using weight-loss drugs to treat obesity in adults, according to draft guidance from the agency that urged countries to take the condition seriously as a chronic disease.The WHO’s expert committee concluded that the popular GLP-1 drugs, first developed by Novo-Nordisk and Eli Lilly, are part of the solution for the long-term treatment of obesity for patients with a body mass index (BMI) of 30 or above, alongside counselling on lifestyle and behaviour changes.It recommended using the drugs to treat obesity for the first time, calling it a critical step toward developing a global standard of care. It is developing separate guidelines for treating children and adolescents.Novo Nordisk to Test Weight-Loss DrugsNovo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat a wide range of health conditions linked to obesity, as it has already begun doing with its blockbuster drug Wegovy.The Danish drugmaker aims to build evidence across both severe and more common obesity-related conditions that affect patients' daily lives, such as knee osteoarthritis and sleep apnea, Martin Holst Lange, head of research and development at Novo Nordisk saidEU Clears Novo's Oral Semaglutide for Heart Risk ReductionThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved Danish pharma major Novo Nordisk’s update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.“Heart problems are the leading cause of disability and death for people living with type 2 diabetes. Therefore, treatments that also address heart problems are key to improving not only health outcomes, but also quality of life – and this approval will help do just that,” said Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk. “This milestone makes semaglutide the only oral GLP-1 RA with proven blood glucose and body weight reduction, as well as cardiovascular benefits.”NVO’s OI Shows Bullish BetsOpen interest for NVO expiring in a year (before Sep 18, 2026 expiration) showed moderately bullish sentiment as Call open interest totaled at 534,364, while Puts stood at 468,000. Put-Call open interest ratio reached 0.88.Source: Option ChartsOption Strategy: Buy Long-Term CallThe expected move for NVO options expiring on Sep 18, 2026 (367 days) is ±$16.39 (29.25%), with a price range of $39.64 - $72.42.The expected move means that IV implies the stock price has a probability of rising toward $72 in a year, giving chances to buy long-term call options for bullish investors.Source: Option ChartsStrategy 1: Buy ITM CallConservative investors may consider deep ITM call options. With high intrinsic value and low time value, these options are less vulnerable to time decay, making them effective for long-term investing or hedging.ITM options carry higher premiums than ATM or OTM ones, but still cost far less than buying the underlying asset outright. This allows investors to control a larger asset value with a smaller capital outlay.Example: Buy the $40 strike call option ( Sep 18, 2026 expiration)$NVO 20260918 40.0 CALL$Max Profit: +∞Net Debit: $1,995 (est.)Breakeven: $59.95Strategy 2: Buy OTM CallOut-of-the-money options come with lower premiums, making them attractive to investors with limited capital but higher risk tolerance. They provide a low-cost way to gain exposure to potential upside in the underlying asset.Example: Buy the $70 strike call option ( Sep 18, 2026 expiration)$NVO 20260918 70.0 CALL$Max Profit: +∞Net Debit: $590 (est.)Breakeven: $75.90","news_type":1,"symbols_score_info":{"NVO":1.1}},"isVote":1,"tweetType":1,"viewCount":1152,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":479282889024040,"commentId":"479282889024040","gmtCreate":1758039335429,"gmtModify":1758039340471,"authorId":3580519485452891,"author":{"id":3580519485452891,"idStr":"3580519485452891","authorId":3580519485452891,"name":"Dan1192","avatar":"https://community-static.tradeup.com/news/b81c29971d6ab7fd0c6f219b749f40ee","vip":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.03","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2007},"crmLevel":12,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":479273100493328,"objectIdStr":"479273100493328","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"我转而购买了leaps，认为NVO的PE比Ely便宜得多。就品牌而言，我们看到这两个品牌同样知名，因此品牌溢价并不能证明PE的差距是合理的。NVO最终应该会赶上<u>向上</u>","text":"我转而购买了leaps，认为NVO的PE比Ely便宜得多。就品牌而言，我们看到这两个品牌同样知名，因此品牌溢价并不能证明PE的差距是合理的。NVO最终应该会赶上<u>向上</u>","html":"我转而购买了leaps，认为NVO的PE比Ely便宜得多。就品牌而言，我们看到这两个品牌同样知名，因此品牌溢价并不能证明PE的差距是合理的。NVO最终应该会赶上<u>向上</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}